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GMC: approaching the abyss
Preservation is well worth the effort
Editor—In his editorial on the General
Medical Council, Smith asks a question that
is in danger of becoming a self fulfilling
prophecy.1 He fairly describes differences of
view in the British medical profession about
governance and the introduction of revali›
dation. He then asks whether it is worth
expending the effort required to ensure the
GMC’s survival on the grounds of its being
dysfunctional, even suggesting that it might
be better to scrap it and start again.
We write as a disparate group of senior
doctors who have been intimately involved
in the debate on the future of the GMC. We
have held differing views about the solutions
that might be offered but are united on the
over›riding importance of professionally led
regulation in partnership with the public. In
this, we concur with Smith that most doctors
wish to practise to the highest possible
standards and that the model of the
intrusive regulatory scrutiny practised by
casino operators is totally inappropriate to
the medical profession.
We believe, from very different perspec›
tives, that the GMC should be allowed to
develop into a better organisation for
doctors and, more importantly, for patients.
Smith’s implication that we should start
looking at fresh alternatives begs the
question as to who would be entrusted do
this work and whether the result would be
any better equipped for the challenges faced
by a 21st century regulator in an increas›
ingly complicated society. Any “fresh start”
would still have to deal with governance and
revalidation, which have been firmly placed
on the current agenda by the present GMC.
The abyss Smith describes is certainly
there, and the GMC may be at its edge.
Despite its current problems, however, the
GMC is the crucible of our professionalism
and without it doctors in this country would
become mere technicians.
Any alternative to professionally led
regulation is unthinkable.
Brian Keighley elected member, Scotland, GMC
Balfron, Stirlingshire G63 0PY
bkeighley@compuserve.com
George Alberti elected member, England
John Chisholm elected member, England
Simon Fradd elected member, England
Barry Jackson elected member, England
Roderick MacSween appointed medical member
General Medical Council, London W1N 6JE
Hamish Meldrum general practitioner principal
Bridlington YO16 4LZ
David Pickersgill general practitioner
North Walsham NR28 0BQ
Mike Pringle professor of general practice
Department of General Practice, Queen’s Medical
Centre, Nottingham NG7 2UH
Dr Keighley receives an honorarium as a medical
screener.
1 Smith R. GMC: approaching the abyss. BMJ
2001;322:1196. (19 May.)
People should be wary of the alternative
Editor—As lay members of the General
Medical Council, we know that we have a
particular responsibility to discharge prop›
erly the GMC’s first duty: the protection of
the public. We are in no doubt that all mem›
bers of the council—medical and lay, elected
and appointed—strive hard to ensure that
patient wellbeing is at the forefront of their
work in standard setting, education, and
registration, as well as in the fitness to prac›
tise procedures. Equally, we support the
major reforms now under way to ensure that
the GMC’s processes and values remain in
tune both with rapidly changing medical
knowledge and practice and with society’s
expectations in a new century.
Radical change is uncomfortable, and
the present debate reflects this, but it is
essentially about means, not ends. Smith
asked whether the GMC is worth saving or
should be replaced by some other form of
regulation altogether.1 The only other alter›
native to professionally led regulation seems
to be a licensing and inspection system run
by government. Experience in other profes›
sions and in other countries suggests that
this would be demotivating for doctors and
much more expensive to operate. In
addition, it could produce conflicts of
interest as full determination of standards
and quality and responsibility for the organ›
isation and resourcing of health become
vested in the same body.
As patients and carers, we want our doc›
tors to be governed by their consciences as
well as their contracts. As lay members of the
public active in the GMC, we are well aware
of the many hours put in by doctors on a
largely unpaid basis. We are convinced that
the active involvement of practising doctors
in all the council’s functions is crucial in
keeping it up to date and maintaining the
trust and support of both the public and the
profession.
The key requirement is to make the
GMC fit for a purpose so that it retains
professional support while meeting the
legitimate expectations of the public. We
think that the changes currently in train,
while capable of some adjustment, must be
carried through to ensure that the GMC
provides an environment in which doctors
continue to enjoy the trust of the public.2
Medical regulation through the GMC with
its growing partnership of medical and lay
members remains the best way of “protect›
ing patients and guiding doctors”; any other
mechanism really could be a step into the
abyss.
Graham Forbes lay member
Sue Leggate lay member
Bob Nicholls lay member
bobnicholls@patrol.i›way.co.uk
Chris Robinson lay member
John Shaw lay member
General Medical Council, London W1N 6JE
1 Smith R. GMC: approaching the abyss. BMJ
2001;322:1196. (19 May.)
2 Ferriman A. Poll shows public still has trust in doctors.BMJ
2001;322;694. (24 March.)
GMC: keeping feet on firm ground
Editor—Smith queries the functions of the
General Medical Council in the new heavily
regulated era for medicine.1 Coordinating
the medical schools, constructing the profes›
sion’s ethical code, and setting baseline
professional standards, are three of them
and would not be done more appropriately
by the state or its agencies. Professional
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regulation (not self regulation) to protect the
public requires a strong partnership
between lay and medical representatives.
Many doctors still think that choosing,
through elections, the doctors on the
regulatory body is better than any alterna›
tive.
Smith concludes that the GMC is failing.
Before seeking fresh alternatives, as he
suggests, many members of the Academy of
Medical Royal Colleges are currently work›
ing hard to seek agreements to the two main
issues of governance and revalidation.
Looking over an abyss can be one way of
learning how important it is to keep your
feet on firm ground.
Denis Pereira Gray chairman
Academy of Medical Royal Colleges, London
W1G 0AE
d.pereiragray@exeter.ac.uk
1 Smith R. GMC: approaching the abyss. BMJ 2001;322:196.
(19 May.)
Time to go
Editor—It is time for the General Medical
Council to go.1 With the possible exception
of its health committee, it has a long history
of being draconian, of incompetence, and of
poor leadership. Its slogan, “Protecting
patients, guiding doctors,” reflects typically
muddled bifocal thinking.
There is no future in revalidation. There
is no instrument that will effectively detect a
dysfunctional doctor with any degree of reli›
ability until the doctor makes a mistake,
when it becomes too late. It has to be
ultimate folly to believe that doctors, appar›
ently unlike any other professional, will will›
ingly report failures and faults themselves. It
is equal folly to assume that fellow workers
will have the time, energy, or motivation to
be watchdog and reporter.
The only solution for the GMC is
disbandment. The work of the health
committee has been of sufficient quality and
standard as to be replaced by an equal.
Gareth Lloyd retired doctor
Manchester M23 1PY
garethllwyd@aol.com
1 Smith R. GMC: approaching the abyss. BMJ
2001;322:1196. (19 May.)
Australia may show way foward for the
United Kingdom
Editor—It seems to be common ground
that regulation of the profession by the
General Medical Council is better than an
alternative, state run, system.1 Ultimately, the
argument concerns the power of the GMC
or some other body to suspend or strike off
a practitioner. Perhaps this is a false choice.
No doctor should be deprived of the
ability to earn a livelihood other than as a
consequence of due process when an
alleged, serious misdemeanour has been
investigated and proved. If that belief is
shared by all, then the question is whether or
not a body, constituted as is the GMC, in its
present or any alternative form, is an appro›
priate body to execute such justice. There is
always a risk of its being perceived as biased,
either towards a favoured son or against a
thorn in the side of the establishment.
One of the former British colonies
resolved this problem many years ago. In
New South Wales the powers of the medical
board do not include suspension or deregis›
tration. The Medical Practice Act gives this
power to the medical tribunal. This com›
prises a judge of the district court; two medi›
cal practitioners appointed by the Medical
Board from panels nominated by the
colleges, the universities, the Department of
Health, and the Australian Medical Associ›
ation; and a lay person chosen from a panel
nominated by the Minister for Health.
The medical board itself makes no
adverse decisions about any doctor, other
than about eligibility for initial registration.
All inquiries that might have an adverse out›
come for a doctor’s right to practise are con›
ducted by committees that are independent
of the board but governed by the Medical
Practice Act.
Might this help the debate in the United
Kingdom?
Peter Arnold former deputy president, New South
Wales Medical Board
Sydney, Australia
parnold@ozemail.com.au
1 Smith R. GMC: approaching the abyss. BMJ
2001;322:1196. (19 May.)
Assessing clinical competence
and revalidation of clinicians
Simulated surgeries would have
advantages
Editor—McKinley et al present cogent
arguments for directly assessing the consul›
tation competence of general practitioners
undergoing revalidation.1 They identify the
required attributes of an assessment as
reliability, validity, acceptability, feasibility,
and educational impact. They do not
mention, however, that the methodology
must also be capable of setting a consistent
standard for pass/fail decisions for every
candidate.
The model that they offer depends on
the judgment of two observers watching 10
consecutive consultations, a task that they
might undertake 12 times in a year. If the
prevalence of insufficient competence was
2% they might encounter it once every four
years. How could they apply a minimum
standard reliably, along with their 1000
assessor colleagues? Just 10 randomly pre›
senting cases will be too few to guarantee an
adequate coverage of consultation skills, and
in the absence of standardisation it will be
hard to achieve a reliability score above 0.5.
Furthermore, the patients will behave differ›
ently if they know that their doctor is under
assessment, thus compromising validity.
The 12 case simulated surgery for the
MRCGP (membership of the Royal College
of General Practitioners) examination is a
model that would overcome these difficul›
ties. The cases are written to test specific
skills; the patients are role players who are
trained to present the same challenge to
each candidate; each examiner observes the
same case throughout the circuit and marks
the candidate’s performance on a predeter›
mined schedule; each candidate is assessed
by all 12 examiners, which minimises bias;
and the pass mark is set by the aggregation
of the judgments of all the examiners, based
on the cases they have marked.
This examination has yielded reliability
figures (coefficient á) in excess of 0.8 in all
six administrations over three years. Face
validity is high (“like a locum surgery”), and
content validity is controlled. The method is
acceptable (universally preferred to video by
eligible candidates). The cost is less than
£350 per candidate if the circuits are full. A
profile of skill subscores can be presented to
the candidate, providing formative feedback.
If the administration was put in place,
regular simulated surgeries could be offered
for revalidation in regional venues through›
out the United Kingdom.
Peter Burrows general practitioner
Abbey Mead Surgery, Romsey, Hampshire
SO51 8EN
pjburrows@interalpha.co.uk
1 McKinley RK, Fraser RC, Baker R. Model for directly
assessing and improving clinical competence and per›
formance in revalidation of clinicians. BMJ
2001;322:712›5. (24 March.)
Video assessments might be effective
screening method
Editor—McKinley et al have shown the reli›
ability and feasibility of their consultation
assessment for examining consultations in
general practice, but they have glossed over
some issues.1
The first such issue is the desirability of
an assessment that tries to be both formative
and summative. Trying to do both at the
same time is generally accepted to be prob›
lematic.2 Although an assessment method
may be valid when used in both ways, the
stress of undertaking a summative assess›
ment may affect performance adversely. The
idea that the five attributes of assessment are
multiplicative is not a true mathematical
concept, and the absence of one does not
negate the others. A summative assessment
does not have to have educational impact
after the assessment: its impact is in setting
the learning aims and objectives for learning
before assessment.
The second issue is that of patient
acceptability. The authors raise the problem
that certain types of patients decline to be
videoed, but it might be expected that the
same patients will decline to have two stran›
gers sitting in the consultation. Videoing can
be intrusive, but around three quarters of
patients forget the camera during the
consultation.3 It is far harder to forget two
extra people.
The third issue is reliability. The table on
bmj.com shows high figures for the validity,
but the number of observers who were
involved is not clear. Increasing the number
of observers is likely to decrease the inter›
observer reliability.
The summative assessment video com›
ponent may only have inter›rater reliability
Letters
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that is “not impressive,” but its reliability in
screening poor performers is reckoned to be
95%, these then undergoing further assess›
ment.4 If the purpose of the exercise is to
select out underperforming general practi›
tioners then a similar tool would be effective,
and possibly cheaper as a screening method.
The problem of finding enough assessors
remains.
Nick Gravestock general practitioner
Measham Medical Unit, Measham DE12 7HR
NickGravestock@aol.com
1 McKinley RK, Fraser RC, Baker R. Model for directly
assessing and improving clinical competence and per›
formance in revalidation of clinicians. BMJ
2001;322:712›5. (24 March.)
2 Brown G, Bull J, Pendlebury M. Assessing student learning in
higher education. London: Routledge, 1997:251.
3 Martin E, Martin PML. The reactions of patients to a video
camera in the consulting room. J R Coll Gen Pract
1985;34:607›10.
4 Campbell LM, Howie JGR, Murray TS. Use of videotaped
consultation in summative assessment of trainees in
general practice. Br J Gen Pract 1995;45:137›41.
Authors’ reply
Editor—Burrows advocates the simulated
surgery used during the MRCGP (member›
ship of the Royal College of General Practi›
tioners) examination as a potential tool for
assessing consultation competence for
revalidation.1 Although this approach has
some commendable features (for example, a
guaranteed range of clinical challenges), we
have previously questioned its credibility, let
alone validity.2
Burrows admits that the simulated
surgery for the MRCGP examination does
not test ability to make diagnoses or to elicit
abnormal physical signs. Surely both are
fundamental skills for all clinicians. The
marking system is also peer referenced and
not criterion referenced, which is essential
for equity in regulatory assessments.
We can reassure both Burrows and
Gravestock about the reliability that can be
achieved with multiple assessors. We have
reported a study of the assessment of the
consultation competence of 180 medical
students involving 86 trained assessors, most
of whom assessed fewer than five students.
The interassessor reliability of pass/fail deci›
sions was 0.94.3
This high level has been replicated in
regulatory assessments of over 140 general
practice registrars in Kuwait, again involving
multiple pairs of assessors, both internal and
external (paper in preparation). With mini›
mal screening, 10 patients provided suffi›
cient clinical challenges. These data confirm
that assessments such as we propose can be
highly reliable when performed by multiple
assessors.
Gravestock asserts that summative
assessment need not have educational
impact and, consequently, that the five
essential attributes of an assessment instru›
ment are not truly multiplicative. All
candidates can benefit from explicit feed›
back on how to improve, and those who fail
have a right to be informed why the
assessors reached their judgment. This is
particularly essential when the livelihood of
a professional colleague is at stake. It is
widely accepted by leading medical educa›
tionalists that the essential attributes are
indeed multiplicative.4 Incidentally, all
assessments can be stressful irrespective of
methodology—this is a fact of life.
We agree with Gravestock that patient
acceptability is important. Indeed, we
emphasised this in our paper. Over 8000
patients have participated in our assessment
studies in Leicestershire,3 Kuwait, and Hong
Kong, and all these involved the presence of
two assessors in the consulting room. The
circumstances are fully explained to
patients, whose consent is mandatory. There
have been few refusals and no adverse com›
ment by the patients.
The authors of both these letters support
our contention that assessing clinical compe›
tence through direct observation must be
central to the revalidation of clinicians. Like
them, we do not underestimate the logistical
implications. Nevertheless, the profession
needs to get on with the task.
Robert K McKinley senior lecturer
rkm@le.ac.uk
Robin C Fraser professor of general practice
Richard Baker professor of quality in health care
Department of General Practice and Primary
Health Care, Leicester Warwick Medical School,
University of Leicester, Leicester General Hospital,
Leicester LE5 4PW
1 Burrows PJ, Bingham L. The simulated surgery—an
alternative to videotape submission for the consulting
skills component of the MRCGP examination: the first
year’s experience. Br J Gen Pract 1999;49:269›72.
2 Fraser RC, McKinley RK. Simulated surgery. Br J Gen Pract
1999;49:753.
3 McKinley RK, Fraser RC, van der Vleuten C, Hastings AM.
Formative assessment of the consultation performance of
medical students in the setting of general practice using a
modified version of the Leicester assessment package.Med
Educ 2000;34:573›9.
4 Van der Vleuten CPM. The assessment of professional
competence: developments, research and practical impli›
cations. Advances in Health Sciences Education 1996;1:41›67.
Results from pilot study using portfolio
and 360° questionnaire
Editor—Regular appraisal of consultants is
to become an integral part of the new NHS.1
McKinley et al addressed the problems inher›
ent in the process.2 We present the initial
results of a pilot study of appraisal using a
portfolio and incorporating a 360° approach.
The project included 20 consultants,
who completed a portfolio based on the
General Medical Council’s guidelines for
revalidation.3 A 360° appraisal questionnaire
was distributed by each consultant to 10
team members and 20 patients; it was based
on the American Board of Internal Medi›
cine validated questionnaire and had ques›
tions on attitude, communication, and skills.3
The return rate for patients was 50% and
that for team members 84%.
No problems were reported with com›
pleting the portfolio questionnaire, and
consultants had no problem with job plans,
including both NHS and independent prac›
tice. The only sections impossible to
complete concerned critical incidents and
complaints. Currently, this information is
not collected centrally in our trust. The
median score for all consultants for both the
team and patients was in the very good or
excellent category. This was reassuring.
Participants thought, however, that the
distribution of questionnaires to patients
and team members should be random and
handled centrally. The anonymity of replies
was considered to be crucial.
The broadest spread of replies came
from clinicians with primary care responsi›
bilities rather than those in service special›
ties. Scoring was consistent for individual
clinicians, with the same spread seen in all
questions. Comments from consultants
shown the overall results of team and patient
questionnaires varied from complimentary
to outright rejection.
The time taken to undertake this pilot
study in only 20 consultants was 40 hours
and 2000 pieces of paper. A large institution
with 500 consultants would need 1000
hours and 50 000 pieces of paper, as well as
2500 hours to conduct appraisal (a mini›
mum of 5 hours per consultant, including
preparation)—716 consultant sessions.
We conclude therefore that appraisal by
portfolio and 360° assessment is feasible if
properly funded. Further work is necessary to
simplify the assessment of team and patient
perception. Emphasis must be placed on
minimising the time spent to reduce the
impact on service delivery. If the process is
handled sympathetically and with common
sense, however, it will be a benefit to all.
Robert Mason assistant medical director
robert.mason@gstt.sthames.nhs.uk
Louisa Zouita audit lead for surgery
Brian Ayers medical director
Office of the Medical Director, Guys and St Thomas
NHS Trust, Guy’s Hospital, London SE1 9RT
1 NHS Plan. A plan for investment. A plan for reform.
www.nhs.uk/nhsplan (accessed 21 June 2001).
2 McKinley RK, Fraser RC, Baker R. Model for directly
assessing and improving clinical competence and per›
formance in revalidation of clinicians. BMJ
2001;322:712›5. (24 March.)
3 General Medical Council. Revalidation: the regular
demonstration by doctors that they remain fit to parctise.
www.gmc›uk.org/revalidation (accessed 21 June 2001).
GMC’s guidance may inhibit
research
Editor—Academic clinical research, includ›
ing the evaluation of new treatments, is cen›
tral to providing high quality, cost effective
care to patients, and it requires the coopera›
tion and goodwill of the patients who volun›
teer to participate. The research process is
externally regulated and monitored by
ethics committees to ensure that patients are
protected.
We welcome the debate on the Data
Protection Act and access to patients’
records,1›3 and wish to raise a related
concern about the General Medical Coun›
cil’s recent guidelines on confidentiality and
their effect on research.4 The GMC’s
document focuses on patients’ rights to
confidentiality and the protection of per›
sonal information. Guidance is important to
protect both patients and doctors, and we
recognise the value of consent in sharing
confidential information.
In clinical research it is now clear that
the physician within a healthcare team who
Letters
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is responsible for a patient’s care “must be
satisfied that patients have been told, or have
had access to written material informing
them, that their records may be disclosed to
persons outside the team” and “that they
have the right to object.”4 The only
exception is where obtaining consent is not
practicable or “where the benefits to an indi›
vidual or to society . . . outweigh the public
and the patient’s interest.”4
Presumably the public interest will rarely
outweigh a patient’s rights and it will, there›
fore, be the responsibility of individual
investigators and practitioners to ensure that
compliance with guidance occurs. Because
of the new guidance, difficulties may arise
between healthcare teams within hospitals
and between hospitals and general practices.
Previously, for instance, a hospital team
interested in investigating a new treatment
for a condition that was mainly seen by gen›
eral practitioners might have used records
from the practice to identify patients to
whom the general practitioner could then
write. However, this would contravene the
GMC’s current guidance, and alternative
strategies have major implications for
resources. In a general practice with links to
several hospital research projects it might be
sensible to ask all patients whether they
would be willing to be approached, but this
would be costly and take time.
These issues will need to be addressed if
the NHS is to remain committed to such
research, and we believe that addressing
these issues is in the best long term interest
of both patients and doctors. Nevertheless,
we are concerned that there has been little
response to the GMC’s document and that
the current position inhibits clinical studies
that might improve patient care.
Stephen J Leslie British Heart Foundation research
fellow
David J Webb professor of clinical pharmacology
d.j.webb@ed.ac.uk
Clinical Pharmacology Unit and Research Centre,
University of Edinburgh, Western General Hospital,
Edinburgh EH4 2XU
1 Strobl J, Cave E, Walley T. Data protection legislation:
interpretation and barriers to research. BMJ 2000;
321:890›2.
2 Al›Shahi R, Warlow C. Using patient›identifiable data for
observational research and audit. BMJ 2000;321:1031›2.
3 Anderson R. Undermining data privacy in health
information. BMJ 2001;322:442›3. (24 February 2001.)
4 General Medical Council. Confidentiality: protecting and pro›
viding information. London: GMC, 2000.
Optimising management of
delirium
Placebo controlled trials of
pharmacological treatments are needed
Editor—In reviewing the management of
delirium, Meagher asserts that antipsychotic
drugs are effective in patients with delirium.1
There is, however, little evidence to support
this assertion. There are no placebo con›
trolled trials of antipsychotic drugs in patients
with delirium. One trial compared anti›
psychotic drugs with benzodiazepines and
found that antipsychotic drugs were superior,
but, given that it is widely acknowledged that
benzodiazepines may worsen delirium, this
result hardly constitutes evidence of efficacy.2
Most clinicians have gained the impression
that antipsychotic drugs speed recovery in
delirium, but their anecdotal observations
must be doubted. Most episodes of delirium
last only several days and will improve when
the patient’s underlying medical condition
resolves. In practice, medical management is
always instituted simultaneously with pre›
scription of antipsychotic drugs. As a con›
sequence, it would be very difficult for
clinicians to isolate the relative effect of an
antipsychotic drug on the resolution of
delirium. Uncontrolled trials suggesting effi›
cacy will present the same problems.
Delirium often manifests with hallucina›
tions, delusions, or thought disorder. In other
psychiatric disorders, such as schizophrenia,
these symptoms are improved by anti›
psychotic drugs, so it is reasonable to postu›
late that these drugs may also help in cases of
delirium. But this hypothesis may be invalid.
Treatments for asthma will not necessarily
help pneumonia, although both illnesses
cause shortness of breath. With so little
evidence to support the use of antipsychotic
drugs in patients with delirium, management
strategies invoking them must be extremely
cautious. Meagher proposes a strategy for
the management of severe behavioural
disturbance in patients with delirium that
could quickly lead to doses of haloperidol of
up to 100 mg per day. Doses this high may be
associated with anticholinergic toxicity and
akathisia—a sense of inner restlessness—that
may worsen agitation rather than quell it.
Such doses also entail an increased risk of
torsades de pointes and the neuroleptic
malignant syndrome.3 4
Moreover, if the analogy with schizo›
phrenia is valid, it is unlikely that patients
would benefit from more than 12 mg of
haloperidol per day.5 Antipsychotic drugs
should be avoided until all non›
pharmacological management options are
exhausted. If they are to be used, haloperidol
is the drug of choice, but doses should not
exceed 12 mg per day. If pharmacological
management of behavioural disturbance is
required after this, then benzodiazepines
should be used, with the understanding that
gaining control of the behavioural distur›
bance may involve an unavoidable perpetu›
ation of the delirium that is driving
disturbance. Obviously, there is an urgent
need for placebo controlled trials.
Christopher James Ryan consultation›liaison
psychiatrist
University of Sydney and Department of Psychiatry,
Westmead Hospital, Westmead, NSW 2145,
Australia
cryan@mail.usyd.edu.au
Competing interests: None declared.
1 Meagher DJ. Delirium: optimising management. BMJ
2001;322:144›9. (27 January.)
2 Breitbart W, Marotta R, Platt MM, Weisman H, Derevenco
M, Grau C, et al. A double blind trial of haloperidol,
chlorpromazine and lorazepam in the treatment of
delirium in hospitalised AIDS patients. Am J Psychiatry
1996;153:231›7.
3 Hunt N, Stern TA. The association between intravenous
haloperidol and torsades de pointes. Three cases and a lit›
erature review. Psychosomatics 1995;36:541›9.
4 Carnoff SN, Mann SC. Neuroleptic malignant syndrome.
Med Clin North America 1993;77:185›201.
5 American Psychiatric Association. Practice guideline for the
treatment of patients with schizophrenia. Washington, DC:
American Psychiatric Association, 1997.
Patients with delirium should be treated
with care
Editor—With respect to Meagher’s review
of delirium and its management we would
like to raise a cautionary note.1 Measures
that protect vulnerable (often elderly)
people from the appearance of delirium,
such as good nursing care and the provision
of an appropriate ward environment, are
always preferable to sedation with psycho›
tropic medication of those who have
developed the condition. Every medical and
nursing student is taught the basic strategies
to be used in managing a delirious
individual that Meagher reviews, yet a visit to
any busy medical ward shows that such prin›
ciples are often forgotten in the face of
shortages of skilled nurses, rapid discharge
of patients, and harassed junior medical
staff.
Chemical restraint of delirious patients
should never be used as a substitute for
simple nursing care. When medication has to
be used, because of the hazards associated
with psychotropic drugs, doses should be
kept to an absolute minimum. Traditionally,
haloperidol has been the mainstay of such
treatment, and in our experience doses at the
absolute lower end of those suggested by
Meagher—for example, haloperidol 0.5›1.0
mg—are sufficient for effective control of agi›
tated behaviour in delirium. As old age
psychiatrists, we are surprised and disturbed
by the high doses of haloperidol suggested in
the article for the pharmacological treatment
of severe disturbance in delirium, since most
of those who will be treated are elderly. If one
followed the treatment plan suggested, then
this could involve giving up to 30 mg
haloperidol intravenously within 30 minutes
and repeating this in the following 30
minutes, with the worryingly reassuring
message that up to 100 mg intravenous
haloperidol every 24 hours is generally safe.
These doses may be suitable for the
acute management of young patients with
functional psychoses who exhibit disturbed
or violent behaviour to which one of the ref›
erences cited in support of this regimen per›
tains,2 but should not be taken as a guide in
elderly medically ill or cognitively impaired
individuals. Two thirds of patients with
delirium have an underlying dementia and
20% of dementia patients have dementia
with Lewy bodies.3 Hence, at least 10% of all
cases of delirium will have dementia with
Lewy bodies, and since this is characterised
by exquisite sensitivity to neuroleptics,4 this
represents a further need for extreme
caution in management.
Naji Tabet specialist registrar
n.tabet@iop.kcl.ac.uk
Robert Howard reader
r.howard@iop.kcl.ac.uk
Old Age Psychiatry, Institute of Psychiatry, Kings
College London, Maudsley Hospital, London
SE5 8AZ
Competing interests: None declared.
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Author’s reply
Editor—These letters highlight the difficul›
ties in attempting to control for the many
factors that influence outcome in treatment
studies of a complex neuropsychiatric disor›
der of multifactorial aetiology. The situation
in patients with delirium is further compli›
cated by the issue of consent. In the absence
of controlled studies, the best available
evidence supports the contention that the
use of typical antipsychotic drugs is associ›
ated with rapid resolution of delirium in
most patients that is evident before the
impact of medical interventions, is inde›
pendent of sedative actions, and correlates
with alterations in measures of monoamine
metabolism.1 Although Ryan thinks that
most cases of delirium will rapidly resolve
regardless of whether antipsychotic agents
are used, accumulating evidence indicates
that this is a misconception and thus
provides support for more aggressive
treatment of these patients.2 Nevertheless,
controlled studies would help clarify the
impact of antipsychotic agents in the
management of delirium.
The theoretical basis for the use of
antipsychotic agents extends beyond the
observation of symptomatic overlap with
functional psychoses and derives from
preclinical and clinical observations regard›
ing the neurochemical disturbances that
relate to delirium.3 Direct extrapolation
from observations that relate to patients
with schizophrenia, for example, should be
made with caution.
The letters also draw attention to some
of the risks of using haloperidol. Partly as a
consequence of the inactivity that has char›
acterised the field of delirium, drug
treatment of delirious patients typically
involves non›licensed use of psychotropic
drugs. Appropriate doses for delirium man›
agement have not been established, but
caution is required in prescribing for
patients with concomitant problems that
confer a greater susceptibility to adverse
effects from antipsychotic agents. The
review emphasises the importance of
non›pharmacological approaches to treat›
ment and advocates haloperidol at low
doses as the most appropriate treatment
where pharmacotherapy is deemed neces›
sary. In addition, the problem of manage›
ment of highly disturbed patients in
intensive treatment settings with potentially
life threatening levels of behavioural distur›
bance is addressed. The management of
elderly patients with suspected Lewy body
dementia, a condition characterised by neu›
roleptic intolerance, would be expected to
differ considerably, and, according to
preliminary evidence, procholinergic
agents may be a useful option in these
cases.4 Clinicians should consider the
relative benefits and risks of treatment with
haloperidol at high doses versus the not
inconsiderable risks of uncontrolled distur›
bance in severely ill delirious patients,
which include death. The available litera›
ture indicates that high doses of haloperidol
have been used with therapeutic success in
such situations.5 The management of this
small number of extremely challenging
cases should not be confused with the rou›
tine management of patients with delirium.
David Meagher consultant psychiatrist
Midwestern Regional Hospital, Limerick, Republic
of Ireland
Competing interests: None declared.
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Withdrawal of Droleptan (droperidol)
Editor—Droperidol is a drug used by
psychiatrists for its sedative and anti›
psychotic effects. It is also, however, a widely
used and highly effective antiemetic when
used at low doses for both the prevention
and treatment of postoperative nausea
and vomiting.1›3 It has a very good side
effect profile at these doses.2 It is also a drug
that is commonly used in combination
with morphine for patient controlled
analgesia, where it has consistently been
shown to reduce the incidence of opiate
induced nausea and vomiting.4 A recent
review suggests that it is the only antiemetic
with any evidence of efficacy in those
circumstances.5
It surprised us therefore to learn that
Janssen›Cilag withdrew this useful drug on
31 March 2001. We appreciate that there
may be a problem with the chronic usage of
this drug in a psychiatric setting, the
concerns being about the potential effect of
droperidol on the cardiac QT interval. We
find it hard to believe that this makes it un›
viable for Janssen›Cilag to continue to
produce the injectable preparation for its
perioperative uses, given its presence in
most anaesthesia rooms. In this setting, the
small doses used and the short term admin›
istration of the drug make it unlikely that the
same problems would occur as in continu›
ous treatment with high doses.
We understand that an assessment of the
risks and benefits assessment has been
carried out, which led Janssen›Cilag to with›
draw droperidol voluntarily, but we seriously
doubt whether its short term, low dose use
was included in this. Janssen›Cilag is the sole
manufacturer of branded droperidol, and
we are unaware of any generic alternative. It
is likely that when supplies become
exhausted soon after the withdrawal date we
will have to turn to more expensive alterna›
tives with its consequences for the national
drug bill.
J Haines anaesthetic specialist registrar
P Barclay consultant anaesthetist
T Wauchob consultant anaesthetist
Liverpool Women’s Hospital, Liverpool L7 8SS
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Animal research
Journal editors could help raise profile of
three Rs of animal research
Editor—The RSPCA (Royal Society for the
Protection of Cruelty to Animals) believes
that the use of laboratory animals presents
an ethical dilemma that affects everyone.
Animals are used for a broad range of
purposes, and thus it is not possible or con›
structive to make sweeping statements about
scientific validity, justification, or suffering.
Issues subject to such polarised debate are
inevitably difficult to resolve. In this case,
sentient animals capable of suffering are
involved.
The human race has a moral imperative
to reduce the pain, suffering, and distress
that it inflicts on other animals to an
absolute minimum. In the case of animal
experiments, the principle of the three
Rs—replacement, reduction, refinement1—is
an excellent practical starting point, and the
RSPCA is committed to promoting and
supporting it. Greater consideration is now
given to implementing this concept, but it is
not universally applied (or understood), and
much is still to be achieved. One likely
reason for this is that the three Rs are often
seen as a separate issue and not part of
mainstream life sciences.
One way to raise the profile of the three
Rs, and push for them to pervade the whole
of the life sciences, would be for journal edi›
tors to insist that published papers include
comprehensive information about the life›
time experiences of the animals involved.
This could include their source, transport,
husbandry and care, group sizes and
structure, enrichment, what was actually
done to the animals, protocol refinements,
welfare problems (and what was done about
them), and the animals’ eventual fate (and
why).
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Journal space is at a premium, but it is
possible to convey this information in
surprisingly few words.2 3 Such detail would
provide guidance for other researchers
wishing to improve animal welfare and
reduce suffering, as well as giving other
interested parties an insight into what labo›
ratory animals actually experience and why.
This would help to depolarise the debate
and enable people with an interest to
contribute to it in an informed and
constructive way.
Although the BMJ rarely publishes
animal research, perhaps it would consider
this kind of comprehensive editorial policy
to help steer the debate towards the middle
ground so that it can go further, faster.
Penny Hawkins senior scientific officer
Research Animals Department, RSPCA, Horsham,
West Sussex HH13 7WN
Research_Animals@rspca.org.uk
1 Smith R. Animal research: the need for a middle ground.
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3 Smith JA, Birke L, Sadler D. Reporting animal use in scien›
tific papers. Lab Anim 1997;31:312›7.
Ethics committees have influenced
animal experiments in Sweden
Editor—The debate in the United King›
dom on animal research1 and the impend›
ing Home Office review of the system2
prompted us to scrutinise the influence that
ethics committees have had on animal
experimentation in Sweden.
In Sweden the review of animal experi›
mentation by animal ethics committees was
made compulsory in July 1979. Until 1998
the decisions of the seven regional commit›
tees were advisory; after that date they
became regulatory. Scientists may, if their
application is rejected, appeal to a higher
court.
We analysed whether and how the com›
mittees have approved the applications
subject to minor changes. We explored
the main reasons for these conditions and
how their frequency varied over time by
analysing protocols from the meetings of
three ethics committees (Jan 1989›Sept
2000). Altogether 10 432 applications were
processed: 7895 were approved, 1907 were
approved with modifications, 427 were post›
poned, 105 were rejected, and the applicants
withdrew 98. Some applications required
more than one modification before
approval. The table shows how the modifica›
tions to project applications that were
required by the ethics committees before
approval may be grouped.
The frequency of modifications required
by the ethics committees varied over the
years from 10% to 30% (overall average
18%). The three year moving average
showed an increasing trend from 16% to
29% during 1999 and 2000. This may reflect
a media debate during this period on the
ethics committees’ role, which was initiated
by a government investigation.3
The areas that the ethics committees
focused on has varied with time. In recent
years pain relief and ensuring the presence
of a licensed supervisor seem to have
received increasing attention, whereas the
interest in introducing earlier humane end
points seems to be decreasing.
About three quarters of the modifica›
tions may be categorised as refinement with
respect to animal welfare, and the modifica›
tions requested have had a positive influence
on project designs. The systems in the
United Kingdom and Sweden cannot,
however, be directly compared. The Home
Office Inspectorate has played an active and
professional part in the United Kingdom in
improving project applications through dia›
logue with individual applicants. The intro›
duction of ethics committees in the United
Kingdom might simply result in this impor›
tant activity being moved from the inspec›
torate to being a responsibility of an ethics
committee.
Jann Hau professor
Jann.Hau@bmc.uu.se
Hans›Erik Carlsson associate professor
Joakim Hagelin research fellow
Department of Physiology, Division of Comparative
Medicine, University of Uppsala, BMC Box 572,
SE›75123 Uppsala, Sweden
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Three Rs should be registration,
randomisation, and reviews (systematic)
Editor—Having found no reliable evidence
from human clinical research about how
much fluid should be given in the resuscita›
tion of bleeding trauma patients, I am work›
ing with others on a systematic review of
controlled trials of fluid replacement in ani›
mal models.1 To date we have identified
about 70 controlled trials.
Some trials are properly randomised but
many are not. The potential for selective
publication of trials showing more promis›
ing treatment effects is considerable, and few
if any of the trials set their results in the con›
text of a systematic review of all previous
trials. Reducing bias is as important in
animal research as in clinical research, and it
would seem appropriate to apply the
strategies used to improve the quality of
clinical research to improve animal research.
I therefore propose the following three Rs of
animal research:
x Registration: prospective registration of
all trials in animals to reduce the potential
for publication bias
x Randomisation: proper randomisation to
reduce the potential for selection bias
x Reviews: systematic reviews to reduce
bias and increase precision.
Ian Roberts senior lecturer in epidemiology
Institute of Child Health, London WC1N 1EH
ian.roberts@ich.ucl.ac.uk
1 Roberts I, Evans P, Bunn F, Kwan I, Crowhurst E. Is the
normalisation of blood pressure in bleeding trauma
patients harmful? Lancet 2001;357:385›7.
Would middle ground approach give
“added value”?
Editor—Forty years ago, before animal
rights militancy had driven animal research
behind a wall of secrecy, the University of
Manchester invited an antivivisection group
to tour its animal research laboratories and
meet the research scientists. My friend, an
animal rights activist with a highly polarised
viewpoint, was determined to confront these
“animal torturers.” When he returned he
was, surprisingly, full of praise for the
researchers.
He admired the university’s courage in
opening its laboratory doors and facing
frank discussion with ‘‘the enemy.” He found
that the researchers, far from being the
crazed animal torturers of his imagination,
were reasonable and caring. They accepted
proposals that the animal rights group put
forward for improvements in the quality of
life of the laboratory animals, and a follow
up visit confirmed progress.
Aggression projected on to this animal
research laboratory was unsustainable once
a cooperative relationship had been estab›
lished. When I drew attention to the
turnaround in my friend’s views he rational›
ised it by saying, “I haven’t changed my mind
about animal research. This laboratory is
different from the others—it genuinely cares
about its animals.”
Was this laboratory different from
others? Perhaps it was, because it invested in
communication and contact rather than
condemnation and distance, or perhaps
because it took a long and sensitive look at
its activities in relation to the prevailing sen›
timent in society. A common pitfall for
animal experimentation is that familiarity
breeds contempt. I have encountered very
caring doctors, scientists, and vets who
became inured over time to what they were
doing to sentient creatures in the name of
medical or veterinary research.
Both sides of the animal research debate
regale us with visions of how good life could
be for humans or animals if we would just
give them a free hand. Both sides are willing
to torment, maim, and kill, as required. How
many of these visions are fantasies, I
wonder? How many are worth the price that
society may have to pay?
Reasons for modification requested by ethics
committee 1989›2000
Modification requested by committee No
Improvement of project design 442
Improvement of euthanasia method 212
Limiting animal number 201
Improved anaesthesia 198
Improved animal housing/husbandry 188
Earlier end point, general 187
Earlier end point, specific 156
Lack of licences/informed consent 137
Ensure licensed supervisor present 102
Improved pain relief 86
Formal errors in application 70
Other 37
Consult veterinarian 11
Total 2027
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We need visions to further our quality of
life, including the vision of living harmoni›
ously with other creatures. Should our
society facilitate all the visions that people
seek to promulgate? If not, how can we weed
out those that are about ignorance, personal
ambition, projected emotions, or commer›
cial greed?
All sectors of society have a part to play.
I have proposed a model for such coopera›
tion in the welfare of farm animals that
could easily be extended to medical research
(www.pighealth.com).
Michael Meredith director
Pig Disease Information Centre, Lolworth,
Cambridgeshire CB3 8DS
pdic@btinternet.com
More funding must go towards finding
alternative non›animal methods
Editor—Throughout the recent, highly
emotive debate regarding animal experi›
mentation and the fate of the medical
research firm Huntingdon Life Sciences1
one crucial factor has been ignored—
namely, the importance of non›animal alter›
native methods. The Fund for the Replace›
ment of Animals in Medical Experiments
(FRAME) is a charity that funds research
into the development of alternative methods
that do not require the use of animals. We
were pleased to see Smith’s editorial, which
acknowledged the crucial role that alterna›
tive methods can have in bringing about a
reduction in the use of animals in research
and testing.2
British and European law dictates that
animals can be used only when no
non›animal alternative is available. The
development of reliable alternative methods
is the best way of achieving the fund’s
ultimate goal of eliminating the need for live
animal experiments.
Current levels of funding for research
into alternative methods are disappointing.
If the government wants the decline in the
number of tests on animals to continue then
this funding must be dramatically increased.
As well as the government, the industries
that currently rely on animal research to
develop and market their products could
support this research into non›animal
methods. The Fund for the Replacement of
Animals in Medical Experiments would like
to see the industries putting considerably
more of their resources into developing
alternative methods.
The development and validation of non›
animal methods is long and expensive. The
rewards, though, are potentially great in
terms of the benefits to science and to
animal welfare.
Samantha Gray scientific officer
FRAME (Fund for the Replacement of Animals in
Medical Experiments), Nottingham NG1 4EE
sam@frame›uk.demon.co.uk
1 MacDonald R. How animal passions became aroused.BMJ
2001;322:244. (27 January.)
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Various fallacies persist in vivisection
debate
Editor—MacDonald might not have pro›
duced such a favourable review of Croce’s
book on the ethics of experimenting on ani›
mals had she had the time and inclination to
research his claims that animal research is
scientifically flawed.1
Thalidomide was never tested in preg›
nant animals before its use in patients. After
the first publication describing fetal abnor›
malities in babies whose mothers had taken
thalidomide during pregnancy the drug was
shown to be teratogenic in rats, mice,
hamsters, rabbits, and three species of mon›
keys. The mandatory teratogenic tests on
potential medicines instituted by the regula›
tory authorities as a result of the thalido›
mide disaster prevented a similar tragedy
with the oral acne treatment retinoin. This
medicine, because of its efficacy, was
marketed despite its known teratogenicity in
laboratory animals. Since it was labelled as
having a confirmed teratogenic risk, only a
few cases of fetal abnormality occurred as a
result of inadvertent exposure.
The claim that isoprenaline is well toler›
ated in cats at doses 175 times greater than
those considered safe for humans is also
incorrect. The human data were gathered
from patients taking isoprenaline during the
hypoxic conditions of an asthma attack; if
cats are rendered similarly hypoxic they also
become sensitive to the cardiotoxic actions
of isoprenaline.
The antivivisection literature is replete
with emotive propaganda and exaggerated
claims of “bad science.” A definitive
examination of the literature, however,
generally exposes criticisms as spurious.
Their perpetuation in books such as Vivisec›
tion or Science does nothing for the ethical
debate.
J H Botting retired
51 Woodbourne Avenue, London SW16 1UX
r.botting@qmw.ac.uk
1 MacDonald R. Vivisection or science? An investigation
into testing drugs and safeguarding health [book review].
BMJ 2001;322:115. (13 January.)
Wyeth responds to news story
on oral contraceptives and
DVT
Editor—In a News article, van Heteren
reports on a Dutch radio broadcast about
the issue of deep venous thrombosis and
third generation oral contraceptives.1
There is no truth in the allegation made
in the broadcast that Wyeth suppressed the
results of a research study. The study report
was provided to the European Agency for
the Evaluation of Medicinal Products in
April 2000, and to other regulatory authori›
ties. To repeat this allegation, and particu›
larly to give it prominence in the title of the
article, is irresponsible; this is a serious and
unresolved scientific debate.
It is important to determine why there
are reported differences between various
studies carried out on the United Kingdom
general practice research database. As we
have made clear in past rapid responses to
the BMJ, to help resolve this issue Wyeth has
repeatedly requested independent scientific
review of studies of combined oral contra›
ceptives using the general practice research
database.2
We reject absolutely the reported asser›
tion by Dr Alexander Walker, an epidemi›
ologist at Harvard School of Public Health
in the United States, that the differences in
results are due to the source of funding.
In our opinion it is the quality of the study,
not whether it is industry sponsored or
“independent,” which should be the most
important criterion for reviewers.
Many research studies are not submitted
for publication. The study in question added
nothing to scientific knowledge on the
subject, and the decision was taken quite
properly not to submit it for publication.
The study was not designed to look at
deep venous thrombosis as a primary end
point. In addition, it had major design and
implementation errors—including that the
definition of current users allowed for the
possibility that women could have stopped
treatment and still be considered a current
user; cases and controls were not matched
by practice, which increases the possibility of
prescriber bias; and patients with arterial
events (for example, arterial retinal events)
were included in the group with deep
venous thrombosis as well as patients who
had recently delivered a baby or had surgery
(both these factors are predisposing factors
for venous thrombosis).
Wyeth remains committed to the resolu›
tion of this important public health issue
through rigorous scientific evaluation.
P Brock medical director Europe
Wyeth Ayerst, 555 East Lancaster Avenue,
St Davids, PA 19087, USA
brockpg@wai.wyeth.com
1 Van Heteren G. Wyeth suppresses research on the pill,
programme claims. BMJ 2001;322:571. (10 March.)
2 De Laat W, Raff R, Brock P. Pitfalls of pharmacoepidemi›
ology. bmj.com 2000. www.bmj.com/cgi/eletters/321/
7270/1171#EL3 (accessed 5 June 2001).
C reactive protein and acute
phase of ischaemic stroke
Editor—Higher C reactive protein concen›
trations indicate increased risk of coronary
and cerebrovascular events in otherwise
healthy individuals1 and a worse prognosis
in myocardial infarction2 and ischaemic
stroke.3 According to Pepys and Berger, the
available data support its potential role as a
marker of cardiovascular risk.4 To be of clini›
cal use, however, the protein must have an
independent prognostic value over and
above that of the data already routinely
available.
In patients with acute myocardial infarc›
tion or ischaemic stroke the extent of necro›
sis is the main but not the only determinant
of prognosis. Age and vascular comorbidity
are not necessarily related to infarct size but
are nevertheless important predictors of
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prognosis. The reasons for a variable
response to the necrotic insult are probably
multiple and require a clear understanding
as they may represent independent addi›
tional determinants of prognosis.
I looked again at data that colleagues
and I obtained in a cohort of patients after
ischaemic stroke.3 The C reactive protein
concentrations increased (>5 mg/l) in about
three quarters of patients within 24 hours
after ischaemic stroke, and higher values
were significantly associated with large
infarct size (60% (n = 87/146) v 26%
(n = 12/47); P < 0.0001, ÷2 test) and worse
outcome (36% (n = 52) v 9% (n = 4);
P = 0.0008, log rank test). Smaller increases
were reported in patients with small infarcts
(median 8 mg/l (25th to 75th centile 3.8 to
26.3 mg/l) v 18 mg/l (10 to 35 mg/l);
P = 0.0002, Mann›Whitney U test) and deep
infarcts (8 mg/l (3 to 26 mg/l) v 19 mg/l (10
to 46 mg/l); P < 0.0001).
The strong association between infarct
size and increased C reactive protein
concentrations may result from accurate
quantification of cerebral infarction by com›
puted tomography and from a variable
intensity of the acute phase response to
inflammatory stimuli (in this case, the extent
of cerebral infarction). This possibility is
suggested by the observation that 24 hour
concentrations were much higher in
patients with previous raised concentra›
tions.5
If the intensity of the acute phase
response was not proportional to the
intensity of the inflammatory stimulus, the
variable increase in the C reactive protein
concentration might not just be a con›
sequence of late recanalisation or persistent
occlusion of the infarct related artery. Thus
the prognostic importance of the 24 hour
concentration may be related partly to
the extent of the necrosis and partly to the
unknown individual determinants of
the intensity of the acute phase response.
C reactive protein might indicate the
inflammatory status during the acute
phase of ischaemic stroke and might aid in
current challenges posed in secondary
prevention.
Mario Di Napoli consultant neurologist
Department of Neurology and Neurorehabilitation,
Casa di Cura Villa Pini d’Abruzzo, 661080 Chieti,
Italy
mariodinapoli@katamail.com
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What’s in a name?
To be medicine for the elderly, or not to be
Editor—The specialty of geriatric medicine
has not settled on a name, so I was interested
to find out which name was the most popu›
lar. Additionally, I want to make a case for
the use of a single name.
The “geriatric medicine” and “medicine”
subsections of the BMJ’s classified jobs
section were surveyed for six months (May
to October 2000 inclusive). The job title dis›
played in the heading or departmental title
for each post was recorded. Jobs in all grades
were recorded, providing the post had a
“geriatric” component.
Altogether 478 posts in “geriatric medi›
cine” were advertised in 24 issues. The table
shows the frequency with which each job
title was cited. Commonest was “medicine
for the elderly” (116 advertisements; 24%),
then “geriatric medicine” (100; 21%), and
“care of the elderly” (96; 20%). The words
“medicine” or “medical” were used in 317
entries (66%).
The word “geriatrics” was coined by
Nascher in 1909 from the Greek geros,
meaning old man, and iatrikos, meaning
“pertaining to a physician” (from iatreia:
cure).1 But geriatrics has not settled on a
generic name for itself like similar specialties
that combine titles, such as paediatrics or
orthopaedics, perhaps because the term is
thought to be stigmatising by many patients,
the public, and some medical staff.
Having multiple titles for a single
specialty implies impermanence and uncer›
tainty, and it could increase confusion as to
the function of the specialty. The BMJ and
royal colleges have always called it “geriatric
medicine.”
I propose that departments should
follow this established lead, but we must
recognise that there are simply too many
barriers to the universal adoption of the
term “geriatric medicine.” I believe that the
English version of “geriatrics”—that is,
“medicine for the elderly”—would be less
troubling to the non›geriatrician, as well as
being a term already included in two thirds
of departmental names.
The National Service Framework for Older
People requires that elderly people be treated
with equality2; our specialty needs a single
title that can be used when bidding for the
health resources that older people are due. If
the specialty is to continue as a specialty, it
needs to establish to which mast it will nail
its flag. The late Bernard Isaacs, professor of
geriatric medicine at Birmingham Univer›
sity, said: “It is better to change the fame of
geriatrics, than the name,” but it is more
realistic for us all to practise medicine for
the elderly.3
Richard Day consultant physician
Department of Medicine for the Elderly, Poole
Hospital, Dorset BH15 2JB
1 Nascher IL. Geriatrics. New York Medical Journal
1909:358›9.
2 Department of Health. National service framework for older
people. London: DoH, 2001.
3 Isaacs B. The challenge of geriatric medicine. Oxford: Oxford
University Press, 1992.
Tautology, or not tautology
Editor—Am I the only person to be
irritated by the term “coronary heart
disease,” which graces the title of our
national service framework and has become
increasingly accepted in medical literature?1
No doubt it took a working committee
many hours at great expense to coin the
term, but surely coronary artery disease,
ischaemic heart disease, coronary disease, or
heart disease would be more appropriate? If
tautology has become an accepted product
of medical spin can we look forward to using
pulmonary lung function tests to assess
asthma or dyspepsia guidelines for the
gastric stomach?
Are there any tsars out there who can
throw light on this issue?
Fiona Gilroy general practitioner
Jubilee Field Surgery, Wiltshire SN14 6DQ
1 Department of Health. National service framework for
coronary heart disease. London: DoH, 2000.
Job titles displayed in the geriatric medicine and medicine sections of the BMJ ’s classified section,
May›October 2000
Departmental title
No (%) of entries
(n=478) Departmental title
No (%) of entries
(n=478)
Medicine for the elderly 116 (24) Integrated medicine for the elderly 2 (0.4)
Geriatric medicine 100 (21) Special responsibility for the elderly 2 (0.4)
Care of the elderly 96 (20) Age related medicine 2 (0.4)
Elderly medicine 48 (10) Adult medicine 2 (0.4)
Elderly care 31 (6) Care of older people 2 (0.4)
Integrated medicine 20 (4) Care of the elderly medicine 2 (0.4)
Elderly care medicine 15 (3) Medical services for elderly people 2 (0.4)
Geriatrics 13 (3) Medical services for older people 2 (0.4)
Elderly services 5 (1) Elderly 2 (0.4)
Health care of the elderly 4 (1) Medical health care of the elderly 1 (0.2)
Health care of older people 4 (1) Integrated general medicine 1 (0.2)
Medicine for elderly people 3 (1) Medicine of the elderly 1 (0.2)
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